EUVIMEDEUVIMED entdecken
Crossref

Cladribine Is Associated With Stable Cortical Gray Matter Lesion Burden in Multiple Sclerosis: A 7T MRI Study

Jonathan Zurawski iD, Shahamat Tauhid, Brian C Healy, Renxin Chu, Maria K Houtchens, Youmna Jalkh, Samar Khalil, Molly Quattrucci, Farrah J Mateen, Salvatore Napoli, Syed Rizvi, Tarun Singhal und 1 weitere

Journal of Neuroimaging · 2025

DOI: 10.1111/jon.70032 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Neuroimaging, 2025. Verfasst von Jonathan Zurawski und 12 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Neurology, Brigham & Women's Hospital Multiple Sclerosis Center, Ann Romney Center for Neurological Diseases, Laboratory for Neuroimag…. Hauptthemen laut MEDLINE: Cladribine, Magnetic Resonance Imaging, Gray Matter, Immunosuppressive Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: EMD Serono.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Purpose Cladribine, an FDA‐approved disease‐modifying immunotherapy for multiple sclerosis (MS), penetrates the CSF and mitigates T cells and B cells, and thus may impact the development of cortical gray matter lesions (CLs) and leptomeningeal enhancement (LME). 7T MRI is a highly sensitive tool for monitoring these outcomes in relapsing‐remitting (RR) MS.

Methods

MS subjects ( n = 19, age [mean ± standard deviation]: 48.8 ± 10.0 years, 63.1% RRMS, 36.9% secondary progressive MS, Expanded Disability Status Scale [EDSS] score 4.1 ± 2.0) underwent 7T MRI with 0.7‐mm 3 voxels within a mean 1.9 months of oral cladribine initiation and ∼1 year later in this real‐world study. CLs and LME were quantified by an expert. Wilcoxon signed rank tests and paired t ‐tests compared baseline to follow‐up data.

Results

A total of 88.2% of subjects had CLs at baseline (mean 14.1 CLs/patient, range 1–77). No subjects accrued new CLs, and CL volume remained stable (0.33 ± 0.48 mL baseline vs. 0.31 ± 0.46 mL follow‐up, p = 0.22). LME was found in 88.9% of subjects at baseline. LME foci number was stable in seven (41.2%), increased in five (29.4%), and decreased in five (29.4%) subjects at follow‐up, but overall LME burden was stable (3.1 ± 1.8 vs. 3.2 ± 1.6 foci per subject, p = 1.0). No EDSS or timed 25‐foot walk change was noted (both p > 0.35). No subjects had clinical relapses or new T2 or gadolinium‐enhancing white matter lesions during the study.

Conclusion

These observational data suggest that cladribine therapy stabilizes cortical demyelination in MS over the first year of treatment. Overall, LME burden remained stable over 1 year; however, within‐subject resolution and accrual were noted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CladribineMagnetic Resonance ImagingGray MatterImmunosuppressive AgentsMultiple Sclerosis, Relapsing-RemittingMultiple SclerosisHumansMaleFemaleMiddle AgedAdult

Stichwörter der Autor:innen

7T MRIcladribinecortical lesionsmultiple sclerosis

Substanzen

CladribineImmunosuppressive Agents

Autor:innen und Institutionen

  • Departments of Neurology, Brigham & Women's Hospital Multiple Sclerosis Center, Ann Romney Center for Neurological Diseases, Laboratory for Neuroimaging Research, Harvard Medical School, Boston, Massachusetts, USA.
  • Departments of Biostatistics, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Departments of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Neurology Center of New England, Foxborough, Massachusetts, USA.
  • Multiple Sclerosis Center of Rhode Island, Brown University Medical School, Providence, Rhode Island, US.
  • Departments of Radiology, Brigham & Women's Hospital Multiple Sclerosis Center, Ann Romney Center for Neurological Diseases, Laboratory for Neuroimaging Research, Harvard Medical School, Boston, Massachusetts, USA.

ORCID-Profile: Jonathan Zurawski, Rohit Bakshi

Förderung

  • EMD Serono

Zitieren

APA

Zurawski, J., Tauhid, S., Healy, B. C., Chu, R., Houtchens, M. K., Jalkh, Y., Khalil, S., Quattrucci, M., Mateen, F. J., Napoli, S., Rizvi, S., Singhal, T., & Bakshi, R. (2025). Cladribine Is Associated With Stable Cortical Gray Matter Lesion Burden in Multiple Sclerosis: A 7T MRI Study. Journal of Neuroimaging. https://doi.org/10.1111/jon.70032

Vancouver

Zurawski J, Tauhid S, Healy BC, Chu R, Houtchens MK, Jalkh Y, et al. Cladribine Is Associated With Stable Cortical Gray Matter Lesion Burden in Multiple Sclerosis: A 7T MRI Study. Journal of Neuroimaging. 2025. doi:10.1111/jon.70032

BibTeX
@article{Zurawski2025,
  author = {Zurawski, Jonathan and Tauhid, Shahamat and Healy, Brian C and Chu, Renxin and Houtchens, Maria K and Jalkh, Youmna and Khalil, Samar and Quattrucci, Molly and Mateen, Farrah J and Napoli, Salvatore and Rizvi, Syed and Singhal, Tarun and Bakshi, Rohit},
  title = {Cladribine Is Associated With Stable Cortical Gray Matter Lesion Burden in Multiple Sclerosis: A 7T MRI Study},
  journal = {Journal of Neuroimaging},
  year = {2025},
  doi = {10.1111/jon.70032}
}
Kostenlos starten →